Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod vs placebo in metastatic castration-resistant prostate cancer
CTR20130169Phase 3Suspended
- Sponsor
- Active Biotech AB
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tasquinimod in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Active Biotech AB. Started Apr 2014; status: suspended.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20130169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130169.